
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
https://www.pharmacytimes.org/on-demand/a-managed-care-review-of-unmet-medical-needs-new-treatments-and-health-economics-associated-with-schizophrenia






